Prestarium Arginine Combi 5mg/1.25mg 30 tablets — Made in Ireland — Free Delivery

Treatment of essential hypertension in adult patients. prestarium arginine combi is prescribed if additional control of blood pressure is necessary when perindopril is used as monotherapy.

For oral use.

The recommended dose of Prestarium Arginine Combi is 1 tablet per day, preferably in the morning before meals. An individual selection of the dose of the individual components of the preparation may be recommended. In the case of clinical expediency, it is possible to switch from monotherapy immediately to treatment with Prestarium Arginine Combi.

Elderly patients (see SPECIAL INSTRUCTIONS). Treatment should be initiated based on blood pressure and renal function.

Impaired kidney function (see SPECIAL INSTRUCTIONS). In the presence of severe renal dysfunction (creatinine clearance 30 ml / min), treatment with the preparation is contraindicated. For patients with moderate renal impairment (creatinine clearance 30-60 ml / min), it is recommended to start treatment with adequate doses of the individual components of the preparation. Patients with creatinine clearance ≥60 ml / min do not require dose adjustment. Routine medical supervision should include frequent monitoring of plasma creatinine and potassium levels.

Impaired liver function (see CONTRAINDICATIONS, SPECIAL INSTRUCTIONS and Pharmacokinetics). In the presence of severe liver dysfunction, treatment with the preparation is contraindicated. Patients with moderate hepatic impairment do not require dose adjustment.

Caused by perindopril: hypersensitivity to the active substance or other ACE inhibitors; angioedema (angioneurotic edema) in history associated with previous treatment with ACE inhibitors; congenital or idiopathic angioedema; pregnant women or women who plan to become pregnant (see use during pregnancy and lactation); simultaneous use with preparations containing aliskiren in patients with diabetes mellitus or impaired renal function (glomerular filtration rate 60 ml / min / 1.73 m2) (see interactions and pharmacodynamics); extracorporeal therapies that result in blood coming into contact with negatively charged surfaces (see interactions); significant bilateral stenosis of the renal arteries or stenosis of the artery of a single kidney (see special instructions).

Caused by indapamide: hypersensitivity to the active substance or other sulfonamides; severe renal failure (creatinine clearance 30 ml / min); hepatic encephalopathy; severe liver dysfunction; hypokalemia; As a general rule, this medicinal product should not be given in combination with non-arrhythmic agents that may cause torsades de pointes (see Interactions); the period of lactation (see Use during pregnancy and lactation).

Caused by the preparation Prestarium arginine Combi: hypersensitivity to any excipient. Due to the lack of sufficient clinical experience, Prestarium Arginine Combi should not be prescribed to patients on hemodialysis, as well as to patients with untreated decompensated heart failure.

The use of perindopril inhibits the renin-angiotensin-aldosterone system (RAAS) and helps to reduce the loss of potassium in the blood plasma caused by indapamide. 4% of patients treated with Prestarium Arginine Combi develop hypokalemia (potassium level 3.4 mmol/l). The most commonly reported adverse reactions were: dizziness, headache, paresthesia, dysgeusia, visual disturbances, vertigo, tinnitus, arterial hypotension, cough, shortness of breath, abdominal pain, constipation, dyspepsia, diarrhea, nausea , vomiting, itching, rash, muscle cramps and asthenia; when using indapamide - hypersensitivity reactions, mainly dermatological, in patients prone to the development of allergic and asthmatic reactions, and maculopapular rashes.

During clinical trials and / or post-registration use of the preparation, the following adverse reactions were observed, which are distributed according to frequency as follows: very often (≥1 / 10), often (from ≥1 / 100 to 1/10), infrequently (from ≥1 / 1000 to 1/100), rare (≥1/10,000 to 1/1000), very rare (1/10,000), frequency unknown (cannot be determined from the available data).